<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02700100</url>
  </required_header>
  <id_info>
    <org_study_id>XEL-CR-01</org_study_id>
    <nct_id>NCT02700100</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction</brief_title>
  <official_title>Prospective, Non-randomised, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeltis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xeltis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, non-randomised, open label clinical study to assess the safety of&#xD;
      the Bioabsorbable Pulmonary Valved (PV) conduit (PV-001) in subjects &gt; 2 years and &lt; 22 years&#xD;
      of age, undergoing Right Ventricular Outflow Tract (RVOT) reconstruction. It is a first in&#xD;
      man feasibility study which will include 10-12 patients in up to 6 sites in Europe.&#xD;
&#xD;
      The primary objective of the study is to assess the survival rate of subjects at 6 months&#xD;
      following implantation of the Bioabsorbable Pulmonary Valved Conduit (PV-001).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. The survival rate of subjects at 12 months following implantation of the Bioabsorbable&#xD;
           Pulmonary Valved Conduit (PV-001)&#xD;
&#xD;
        2. The percentage of conduit failure at 6 months and 12 months, where conduit failure&#xD;
           includes the need for reintervention or reoperation.&#xD;
&#xD;
        3. The pressure gradient across the pulmonary valve will have an acceptable level at 12&#xD;
           months follow up.&#xD;
&#xD;
        4. The pulmonary regurgitation measured will not exceed a moderate grading at 12 months&#xD;
           follow up.&#xD;
&#xD;
        5. To evaluate the usability of the Bioabsorbable Pulmonary Valved Conduit (PV-001) during&#xD;
           the surgical procedure, using exploratory parameters&#xD;
&#xD;
      Long term safety will be assessed up to 60 months post implantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The survival rate of participants at 6 months following implantation of the Bioabsorbable Pulmonary Valved Conduit (PV-001),, measured by the fact that the patient is still alive at the time of the 6 month FU visit</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The survival rate of participants at 12 months following implantation of the Bioabsorbable Pulmonary Valved Conduit (PV-001), measured by the fact that the patient is still alive at the time of the 12 month FU visit.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of reoperation or reintervention due to PV conduit failure at 6 months and 12 months follow up , measured by the fact that the patient did not have a reoperation or reintervention during the follow up time.</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients with a mean pressure gradient across the area of PV conduit implantation (RV to PA) of less than 40 mm Hg at 12 months follow up, measured with echocardiography at 12 months follow up.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients with pulmonary regurgitation of equal or less than moderate at 12 months follow up, measured with echocardiography at 12 months follow up.</measure>
    <time_frame>12 months</time_frame>
    <description>The degree of pulmonary regurgitation (the percentage of blood that regurgitates back through the pulmonary valve due to valve insufficiency) is defined as:&#xD;
mild if regurgitant fraction is &lt;20%&#xD;
moderate if regurgitant fraction is 20%-40%;&#xD;
severe if regurgitant fraction is &gt;40%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction of the implantability of the Bioabsorbable Pulmonary Valved Conduit (PV-001), measured with a questionnaire given to the implanting surgeon at the time of implantation of the PV conduit (PV-001).</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Pulmonary Valved Conduit (PV-001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioabsorbable Pulmonary Valved Conduit (PV-001) implantation through open surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioabsorbable Pulmonary Valved Conduit (PV-001)</intervention_name>
    <description>The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.&#xD;
The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:&#xD;
Tetralogy of Fallot&#xD;
Truncus Arteriosus&#xD;
Pulmonary Atresia&#xD;
Transposition of Great Arteries with Ventricular Septal Defect (VSD)&#xD;
Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes&#xD;
The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits.</description>
    <arm_group_label>Pulmonary Valved Conduit (PV-001)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient requiring RVOT reconstruction, suitable for 16 mm or 18 mm conduit.&#xD;
&#xD;
          2. Male or Female.&#xD;
&#xD;
          3. Age &gt; 2 years and &lt; 22 years.&#xD;
&#xD;
          4. Right Ventricular to Pulmonary Artery peak gradient &gt; 35mm Hg or moderate or severe&#xD;
             Pulmonary Valve regurgitation (â‰¥3+), or have both.&#xD;
&#xD;
          5. The patient, and the patient's parent / legal representative where appropriate, has&#xD;
             been informed of the nature of the study, agrees to its provisions and has provided&#xD;
             written informed consent by signing the approved informed consent form.&#xD;
&#xD;
          6. The patient, and the patient's parent / legal representative where appropriate, and&#xD;
             the treating physician agree that the subject will return for all required&#xD;
             post-procedure follow up visits and the subject will comply with protocol-required&#xD;
             follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Need for or presence of prosthetic valve at other position.&#xD;
&#xD;
          2. Need for concomitant surgical procedures (outside of the heart).&#xD;
&#xD;
          3. Patients with previously implanted pacemaker (including defibrillators), or mechanical&#xD;
             valves.&#xD;
&#xD;
          4. Active infection requiring current antibiotic therapy (if temporary illness, subject&#xD;
             may be a candidate 4 weeks after discontinuation of antibiotics).&#xD;
&#xD;
          5. Active endocarditis.&#xD;
&#xD;
          6. Leukopenia.&#xD;
&#xD;
          7. Acute or chronic anaemia.&#xD;
&#xD;
          8. Thromocytopenia.&#xD;
&#xD;
          9. Severe chest wall deformity.&#xD;
&#xD;
         10. Right ventricular outflow tract aneurysm.&#xD;
&#xD;
         11. Known hypersensitivity to anticoagulants and antiplatelet drugs.&#xD;
&#xD;
         12. Immunocompromised patient defined as: autoimmune disease, patients receiving&#xD;
             immunosuppressant drugs or immunostimulant drugs.&#xD;
&#xD;
         13. Need for emergency cardiac or vascular surgery or intervention.&#xD;
&#xD;
         14. Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that&#xD;
             has a life expectancy of less than one year.&#xD;
&#xD;
         15. Currently participating, or participated within the last 30 days, in an&#xD;
             investigational drug or device study.&#xD;
&#xD;
         16. Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this&#xD;
             includes the illicit use of cannabis within the last 12 months.&#xD;
&#xD;
         17. Pregnancy.&#xD;
&#xD;
         18. Females who are sexually active and are not willing to use adequate contraceptive&#xD;
             precautions for the next 2 years&#xD;
&#xD;
         19. Subject has medical, social or psychosocial factors that, in the opinion of the&#xD;
             Investigator, could impact safety or compliance with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Carrel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gottsegen GyÃ¶rgy Hungarian Institute of Cardiology, Paediatric Cardiac Centre</name>
      <address>
        <city>Budapest</city>
        <zip>H-1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Jantung Negara, National Heart Institute</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital of Cracow (UCH),</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Malaysia</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2016</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

